{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-002317","form_type":"8-K","ticker":"QURE","cik":"0001590560","company_name":"uniQure N.V.","filed_at":"2026-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.561812+00:00","generated_at":"2026-05-16T11:03:40.480042+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"uniQure schedules Type A FDA meeting for accelerated approval of AMT-130 in Huntington's disease","bullets":["Type A meeting with FDA scheduled to discuss BLA data package for accelerated approval of AMT-130 (Huntington's disease gene therapy).","CEO Matt Kapusta emphasized commitment to constructive dialogue and timely resolution for patients with high unmet need.","Regulatory update expected after receipt of official meeting minutes from the FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-002317","json":"https://secwatch.observer/filing/0001104659-26-002317.json","markdown":"https://secwatch.observer/filing/0001104659-26-002317.md","text":"https://secwatch.observer/filing/0001104659-26-002317.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590560/000110465926002317/0001104659-26-002317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590560/000110465926002317/qure-20260109x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:03:40.480042+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}